Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Abpro Holdings Inc. is a biotechnology firm dedicated to creating sophisticated antibody-based treatments for individuals grappling with immuno-oncology, ophthalmology, and autoimmune disorders. The company's innovative DiversImmune platform is specifically engineered to resolve a key hurdle currently facing the antibody therapeutics sector. Among its leading experimental therapies are ABP-100, designed to combat breast, gastric, and colorectal cancers, and ABP-201, aimed at treating vascular conditions affecting the eye. Abpro Holdings also benefits from important collaborations with Abpro Bio Co. Ltd and NJCTTQ. Established in 2004, the company, originally known as Abpro Corporation, officially adopted its current name, Abpro Holdings, Inc., in November 2024. Its corporate headquarters are situated in Woburn, Massachusetts.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E.